Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

BACKGROUND/AIMS: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication. METHODS: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninf...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yoon Jin, Lee, Yong Chan, Kim, Jung Mogg, Kim, Jin Il, Moon, Jeong Seop, Lim, Yun Jeong, Baik, Gwang Ho, Son, Byoung Kwan, Lee, Hang Lak, Kim, Kyoung Oh, Kim, Nayoung, Ko, Kwang Hyun, Jung, Hye-Kyung, Shim, Ki-Nam, Chun, Hoon Jai, Kim, Byung-Wook, Lee, Hyuk, Kim, Jie-Hyun, Chung, Hyunsoo, Kim, Sang Gyun, Jang, Jae Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289827/
https://www.ncbi.nlm.nih.gov/pubmed/35791797
http://dx.doi.org/10.5009/gnl220055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289827/
https://www.ncbi.nlm.nih.gov/pubmed/35791797
http://dx.doi.org/10.5009/gnl220055

Ejemplares similares